argenx ends the Phase III UNITY trial of efgartigimod SC in Sjögren's disease after futility analysis. Read what this means for patients and the pipeline.

argenx's FB102 met its primary endpoint in a Phase II celiac disease trial on intestinal villus damage. Phase III is next. Read the full results today.

argenx will discontinue its Phase 3 UNITY study of efgartigimod in Sjögren's disease after an interim analysis showed the trial could not meet its.

FB102 met a Phase 2 celiac biopsy endpoint against placebo at day 78 (p=0.0176), and argenx plans Phase 3 development.

NEW YORK CITY, NY / ACCESS Newswire / October 8, 2026 / Levi & Korsinsky notifies investors that it has commenced an investigation into argenx SE ("argenx SE") ...

The decision follows a recommendation from an independent data monitoring committee, which determined following an interim analysis that the study would not be able to achieve its primary endpoint. The immunology group, listed on Euronext and Nasdaq, will now analyze all data collected.

October 8, 2026, 7:00 AM CET Amsterdam, the Netherlands - argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that it will discontinue the...

Study met primary endpoint of change from baseline in the ratio of Vh:Cd (p=0.0176)First Phase 2 evidence that blocking CD122 can prevent gluten-induced intestinal damage in people living with celiac diseaseargenx plans to advance FB102 into Phase 3 development October 8, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced positive topline results from the Phase 2 study evaluating FB102, a first-in-class CD12